Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer

Nikolaos Xenidis (1) , Nikolaos Vardakis (2) , Ioannis Varthalitis (3) , Stylianos Giassas (4) , Emmanouel Kontopodis (2) , Nikolaos Ziras (5) , Ioannis Gioulbasanis (2) , George Samonis (2) , Kostas Kalbakis (2) , Vassilis Georgoulias (2)

1 Department of Medical Oncology
2 Department of Medical Oncology
3 Department of Medical Oncology
4 Department of Medical Oncology
5 Department of Medical Oncology

Mots clés: Pegylated doxorubicin; CPT-11; SCLC; Second-line treatment

Nikolaos Xenidis, Nikolaos Vardakis, Ioannis Varthalitis, Stylianos Giassas, Emmanouel Kontopodis, et al.. Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2010, 68 (1), pp.63-68. ⟨10.1007/s00280-010-1427-5⟩. ⟨hal-00621301⟩